Free Trial
OTCMKTS:HYPMY

Hypera (HYPMY) Stock Price, News & Analysis

$4.71
-0.07 (-1.46%)
(As of 10/17/2024 ET)

About Hypera Stock (OTCMKTS:HYPMY)

Key Stats

Today's Range
$4.60
$4.71
50-Day Range
$4.69
$5.92
52-Week Range
$4.60
$7.90
Volume
53,538 shs
Average Volume
83,103 shs
Market Capitalization
$2.98 billion
P/E Ratio
8.97
Dividend Yield
3.18%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

Receive HYPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hypera and its competitors with MarketBeat's FREE daily newsletter.

HYPMY Stock News Headlines

I want to be very real with you
Listen, I don’t come at my readers this direct very often, but here goes nothing: There is one strategy that has helped change my life and I’d like to think it has changed the lives of some of my readers, too. We’ve had success stories but I won’t even show you here because I don’t want you to get unrealistic expectations since individual results do vary. But the point is, this thing is the real deal. There’s a reason I consider it my flagship, even with all the market advantages I’ve discovered in recent years.
See More Headlines

HYPMY Stock Analysis - Frequently Asked Questions

Hypera's stock was trading at $7.16 at the beginning of 2024. Since then, HYPMY shares have decreased by 34.2% and is now trading at $4.71.
View the best growth stocks for 2024 here
.

Hypera S.A. (OTCMKTS:HYPMY) posted its quarterly earnings data on Thursday, July, 25th. The company reported $0.15 earnings per share for the quarter. The company earned $420 million during the quarter.

Shares of HYPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
7/25/2024
Today
10/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:HYPMY
Fax
N/A
Employees
10,783
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.59 billion
Cash Flow
$0.54 per share
Book Value
$3.26 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.98 billion
Optionable
Not Optionable
Beta
1.04
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (OTCMKTS:HYPMY) was last updated on 10/17/2024 by MarketBeat.com Staff
From Our Partners